rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

Table 4 Caspase-3 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	12.32 ± 0.8ea	11.21 ± 1.05ea	8.86 ± 1.01ea
rAd-p53	5 × 106	0	7.89 ± 1.13ca	6.07 ± 0.97ca	4.32 ± 1.03ca
	5 × 107	0	10.03 ± 1.03ca	8.38 ± 1.04ca	6.03 ± 0.99ca
	5 × 108	0	12.34 ± 1.05ca	10.52 ± 0.89ca	8.31 ± 1.02ca
	5 × 109	0	15.04 ± 1.03ca	11.34 ± 0.55ca	10.12 ± 1.01ca
rAd-p53 + OXA	5 × 106	3.2	22.05 ± 1.01eca	15.67 ± 1.03eca	13.48 ± 1.01eca
	5 × 107	3.2	25.13 ± 1.06eca	18.83 ± 1.02eca	15.32 ± 1.07eca
	5 × 108	3.2	27.24 ± 1.73eca	21.07 ± 1.01eca	18.93 ± 1.06eca
	5 × 109	3.2	35.67 ± 1.03eca	26.16 ± 1.05eca	22.34 ± 1.13eca
Control	0	0	1.32 ± 1.02	1.29 ± 0.97	1.27 ± 0.68

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.